Hengdian Group Capital
Overview
Hengdian Group Capital (HgC) is the strategic investment and corporate development arm of the Hengdian Group, a large Chinese conglomerate, focusing on investments in healthcare, advanced manufacturing, and entertainment sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| 成都海博为药业有限公司 | Oct 2026 | Series B Extension | Co-investor |
| Corxel | Jan 2026 | Series D Extension | Co-investor |
| Guangzhou Jason Anime Culture Co., Ltd. | Dec 2025 | Strategic | Co-investor |
| Solu Therapeutics | Apr 2025 | Series A | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Hengdian Group Capital based?
Hengdian Group Capital is headquartered in Hangzhou, Zhejiang, China.
When was Hengdian Group Capital founded?
Hengdian Group Capital was founded in 2017.
How many portfolio companies does Hengdian Group Capital have?
Hengdian Group Capital has 7 portfolio companies in Caplight's dataset.
What are some companies in Hengdian Group Capital's portfolio?
Recent investments visible on Caplight include 成都海博为药业有限公司, Corxel, Guangzhou Jason Anime Culture Co., Ltd., Guangzhou Jason Anime Culture Co., Ltd., Solu Therapeutics.
What was Hengdian Group Capital's most recent investment?
Hengdian Group Capital's most recent investment on Caplight was in 成都海博为药业有限公司 in 2026.
What sectors does Hengdian Group Capital focus on?
Hengdian Group Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Mobility, Transportation & Logistics, Crypto & Web3, Consumer & Commerce, AI, Data & Cloud Infrastructure, Media, Entertainment & Gaming, Frontier & Industrial Tech.
What company stages does Hengdian Group Capital focus on?
Hengdian Group Capital typically invests at the MultiStage stage.